Molecular Dissection of Microsatellite Instable Colorectal Cancer

Por Vilar, Eduardo, Tabernero, Josep
Publicado em 2013

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life

Por Ciardiello, Fortunato, Tabernero, Josep
Publicado no ESMO Open (2016)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

Por Markman, Ben, Dienstmann, Rodrigo, Tabernero, Josep
Publicado em 2010

Multi-target angiokinase inhibitors to fight resistance

Por Casanovas, Oriol, Salazar, Ramon, Tabernero, Josep
Publicado no Cell Cycle (2014)

Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy

Por Verdaguer, Helena, Tabernero, Josep, Macarulla, Teresa
Publicado no Ther Adv Med Oncol (2016)

Pushing the envelope in the mTOR pathway. The second generation of inhibitors

Por Vilar, Eduardo, Perez-Garcia, Jose, Tabernero, Josep
Publicado em 2011

Micromanaging the classification of colon cancer. The role of the microRNAome

Por Vilar, Eduardo, Tabernero, Josep, Gruber, Stephen B.
Publicado em 2011

Accomplishments in 2008 in the Treatment of Advanced Metastatic Colorectal Cancer

Por Goldberg, Richard M., Meropol, Neal J., Tabernero, Josep
Publicado em 2009

Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs

Por Dienstmann, Rodrigo, Braña, Irene, Rodon, Jordi, Tabernero, Josep
Publicado em 2011

Treatment-related mortality with aflibercept in cancer patients

Por Tabernero, Josep, Hitier, Simon, Derobert, Eric, Van Cutsem, Eric
Publicado em 2014

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

Por Tabernero, Josep, Kunzmann, Volker, Scheithauer, Werner, Reni, Michele, Shiansong Li, Jack, Ferrara, Stefano, Djazouli, Kamel
Publicado no Onco Targets Ther (2017)

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials

Por Hurwitz, Herbert I., Tebbutt, Niall C., Kabbinavar, Fairooz, Giantonio, Bruce J., Guan, Zhong-Zhen, Mitchell, Lada, Waterkamp, Daniel, Tabernero, Josep
Publicado em 2013

Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients

Por Gandhi, Anita K., Shi, Tao, Li, Mingyu, Jungnelius, Ulf, Romano, Alfredo, Tabernero, Josep, Siena, Salvatore, Schafer, Peter H., Chopra, Rajesh
Publicado em 2013

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

Por Prat, Aleix, Carey, Lisa A., Adamo, Barbara, Vidal, Maria, Tabernero, Josep, Cortés, Javier, Parker, Joel S., Perou, Charles M., Baselga, José
Publicado em 2014

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

Por Tian, Sun, Simon, Iris, Moreno, Victor, Roepman, Paul, Tabernero, Josep, Snel, Mireille, van't Veer, Laura, Salazar, Ramon, Bernards, Rene, Capella, Gabriel
Publicado em 2013

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patient...

Por Ciardiello, Fortunato, Adams, Richard, Tabernero, Josep, Seufferlein, Thomas, Taieb, Julien, Moiseyenko, Vladimir, Ma, Brigette, Lopez, Gustavo, Vansteenkiste, Johan F., Esser, Regina, Tejpar, Sabine
Publicado no Oncologist (2016)

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

Por Siena, Salvatore, Tabernero, Josep, Bodoky, Gyorgy, Cunningham, David, Rivera, Fernando, Ruff, Paul, Canon, Jean Luc, Koukakis, Reija, Demonty, Gaston, Hechmati, Guy, Douillard, Jean-Yves
Publicado no ESMO Open (2016)

Impact of Glucose-Lowering Agents on the Risk of Cancer in Type 2 Diabetic Patients. The Barcelona Case-Control Study

Por Simó, Rafael, Plana-Ripoll, Oleguer, Puente, Diana, Morros, Rosa, Mundet, Xavier, Vilca, Luz M., Hernández, Cristina, Fuentes, Inmaculada, Procupet, Adriana, Tabernero, Josep M., Violán, Concepción
Publicado em 2013

Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma

Por Schöffski, Patrick, Guillem, Vincente, Garcia, Margarita, Rivera, Fernando, Tabernero, Josep, Cullell, Martin, Lopez-Martin, Jose Antonio, Pollard, Patricia, Dumez, Herlinde, del Muro, Xavier Garcia, Paz-Ares, Luis
Publicado em 2009

Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors

Por Kopetz, Scott, Tabernero, Josep, Rosenberg, Robert, Jiang, Zhi-Qin, Moreno, Víctor, Bachleitner-Hofmann, Thomas, Lanza, Giovanni, Stork-Sloots, Lisette, Maru, Dipen, Simon, Iris, Capellà, Gabriel, Salazar, Ramon
Publicado no Oncologist (2015)